02:22 PM EDT, 06/06/2024 (MT Newswires) -- Tiziana Life Sciences ( TLSA ) said Thursday that eight of the 10 non-active secondary progressive multiple sclerosis patients receiving intranasal foralumab for at least six months in the expanded access program showed qualitative improvement in neuroimaging.

Further studies are required to confirm these findings, the drugmaker said.

Tiziana said in May that it applied for the US Food and Drug Administration's orphan drug designation for intranasal foralumab.

Shares of the company fell nearly 6% in recent trading.

Price: 0.95, Change: -0.06, Percent Change: -5.94